XSHE
002932
Market cap603mUSD
Dec 05, Last price
18.36CNY
1D
0.60%
1Q
-3.52%
IPO
60.07%
Name
Wuhan Easy Diagnosis Biomedicine Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and diagnostic equipment in China and internationally. Its products portfolio includes molecular diagnostic products, such as drug metabolism genetic testing and pathogen nucleic acid detection kits; and immunodiagnostic and blood gas diagnosis products. The company also provides emergency and critical illness information solutions, including information software products, supporting hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular, kidney, infectious, diabetes, endocrine and metabolic, obstetrics, and gynecology diseases, as well as prenatal and postnatal care, health checkups, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection. The company was founded in 2008 and is based in Wuhan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||